3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
11
Neoplasm Metastasis
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Brain Neoplasms
2
Uterine Neoplasms
1
Urologic Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm, Residual
1
Melanoma
1
HER2-positive Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
fludarabine phosphate
4
Cyclophosphamide
4
blinatumomab
3
Rituximab
3
Lenalidomide
2
Immunotherapy, Adoptive
2
venetoclax
1
trastuzumab deruxtecan
1
tisagenlecleucel
1
pembrolizumab
1
obinutuzumab
1
niraparib
1
nilotinib
1
isatuximab
1
acalabrutinib
1
Zymosan
1
Whole-Body Irradiation
1
Trastuzumab
1
Sodium Chloride
1
Sirolimus
1
Radiotherapy
1
Pentostatin
1
NKTR-255
1
Mycophenolic Acid
1
Melphalan
1
Magnetic Resonance Imaging
1
Immunotherapy
1
Imatinib Mesylate
1
Histamine Antagonists
1
Exercise Test
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neoplasm, Residual
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT06663787
2026-05-13
HER2 CR
Nagoya City University
Active not recruiting
50 enrolled